Denali Therapeutics Inc.
NASDAQ:DNLI
29.6 (USD) • At close November 7, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
---|---|---|---|---|---|---|---|---|---|
Assets: | |||||||||
Current Assets: | |||||||||
Cash & Cash Equivalents
| 127.106 | 218.044 | 293.477 | 507.144 | 79.449 | 77.123 | 218.375 | 39.853 | 30.74 |
Short Term Investments
| 907.405 | 1,118.171 | 571.93 | 962.553 | 335.907 | 387.174 | 187.851 | 138.478 | 0 |
Cash and Short Term Investments
| 1,034.511 | 1,336.215 | 865.407 | 1,469.697 | 415.356 | 464.297 | 406.226 | 178.331 | 30.74 |
Net Receivables
| 2.7 | 5 | 1.226 | 5.674 | 0 | 8.546 | 0.464 | 0.438 | 0 |
Inventory
| 0 | -5 | 0 | 0 | 0 | -8.546 | -0.464 | 0 | 0 |
Other Current Assets
| 26.926 | 36.104 | 30.601 | 20.284 | 14.675 | 16.539 | 3.381 | 3.186 | 2.691 |
Total Current Assets
| 1,064.137 | 1,372.319 | 897.234 | 1,495.655 | 430.031 | 480.836 | 409.607 | 181.955 | 33.431 |
Non-Current Assets: | |||||||||
Property, Plant & Equipment, Net
| 71.637 | 74.524 | 69.608 | 73.464 | 80.655 | 25.162 | 14.923 | 15.262 | 3.168 |
Goodwill
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Goodwill and Intangible Assets
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long Term Investments
| 1.6 | 1.5 | 425.449 | 32.699 | 39.886 | 147.881 | 60.75 | 73.08 | 0.084 |
Tax Assets
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets
| 16.543 | 11.899 | 11.871 | 2.462 | 2.659 | 8.105 | 1.441 | 0.77 | 0 |
Total Non-Current Assets
| 89.78 | 87.923 | 506.928 | 108.625 | 123.2 | 181.148 | 77.114 | 89.112 | 3.252 |
Total Assets
| 1,153.917 | 1,460.242 | 1,404.162 | 1,604.28 | 553.231 | 661.984 | 486.721 | 271.067 | 36.683 |
Liabilities & Equity: | |||||||||
Current Liabilities: | |||||||||
Account Payables
| 9.483 | 2.79 | 4.779 | 1.071 | 2.59 | 1.891 | 2.716 | 1.963 | 1.713 |
Short Term Debt
| 7.26 | 7.318 | 5.453 | 4.69 | 3.665 | 19.088 | 0 | 0 | 0 |
Tax Payables
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Deferred Revenue
| -46.909 | 290.053 | 320.301 | 23.483 | 18.739 | 11.427 | 0 | 0 | 0 |
Other Current Liabilities
| 14.33 | 63.761 | 47.712 | 42.455 | 20.35 | 0.38 | 11.448 | 7.143 | 1.768 |
Total Current Liabilities
| 77.982 | 363.922 | 378.245 | 71.699 | 45.344 | 32.786 | 14.164 | 9.106 | 3.481 |
Non-Current Liabilities: | |||||||||
Long Term Debt
| 44.981 | 53.032 | 58.554 | 64.175 | 68.865 | 0 | 0 | 0 | 0 |
Deferred Revenue Non-Current
| 0 | 0.479 | 4.693 | 317.174 | 43.753 | 57.35 | 0 | 0 | 0 |
Deferred Tax Liabilities Non-Current
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities
| -44.981 | 0.379 | 0.379 | 0.701 | 0.379 | 25.003 | 6.761 | 7.442 | 48.836 |
Total Non-Current Liabilities
| 44.981 | 53.89 | 63.626 | 382.05 | 112.997 | 82.353 | 6.761 | 7.442 | 48.836 |
Total Liabilities
| 122.963 | 417.812 | 441.871 | 453.749 | 158.341 | 115.139 | 20.925 | 16.548 | 52.317 |
Equity: | |||||||||
Preferred Stock
| 0 | 0 | 0 | 0 | 0 | 0 | 486.721 | 348.673 | 48.308 |
Common Stock
| 1.711 | 1.686 | 1.548 | 1.531 | 1.288 | 1.273 | 1.201 | 2.688 | 0.17 |
Retained Earnings
| -1,116.211 | -970.987 | -644.996 | -354.415 | -425.551 | -227.937 | -191.697 | -103.512 | -16.86 |
Accumulated Other Comprehensive Income/Loss
| 0.643 | -6.886 | -2.499 | -0.245 | 0.35 | -0.649 | -0.368 | -0.373 | -48.308 |
Other Total Stockholders Equity
| 0 | 2,018.617 | 1,608.238 | 1,503.66 | 818.803 | 774.158 | 169.939 | 7.043 | 1.056 |
Total Shareholders Equity
| 1,030.954 | 1,042.43 | 962.291 | 1,150.531 | 394.89 | 546.845 | 465.796 | 254.519 | -15.634 |
Total Equity
| 1,030.954 | 1,042.43 | 962.291 | 1,150.531 | 394.89 | 546.845 | 465.796 | 254.519 | -15.634 |
Total Liabilities & Shareholders Equity
| 1,153.917 | 1,460.242 | 1,404.162 | 1,604.28 | 553.231 | 661.984 | 486.721 | 271.067 | 36.683 |